Effects of Dietary Interventions on the Brain in Mild Cognitive Impairment (MCI)

NCT ID: NCT01219244

Last Updated: 2017-07-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2/PHASE3

Total Enrollment

330 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-08-31

Study Completion Date

2016-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study will investigate whether dietary modification could provide positive effects on brain functions in elderly people with mild cognitive impairment.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The age-related degradation of cognitive functions even to the point of neurodegenerative disorders such as Alzheimer's disease are a growing public-health concern with devastating effects.

Referring to animal data, empirical studies, and pilot human trials, dietary modification (caloric restriction, omega-3 fatty acids and resveratrol) should improve cognitive functions such as learning and memory. To test this hypothesis, the researchers study general brain functions in elderly subjects (50-80 years old) with mild cognitive impairment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Mild Cognitive Impairment

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Caloric restriction

Group Type EXPERIMENTAL

caloric restriction

Intervention Type BEHAVIORAL

6 months of caloric restriction (15 %)

omega-3 supplementation

Group Type EXPERIMENTAL

omega-3 supplementation

Intervention Type BEHAVIORAL

6 months of omega-3 supplementation

resveratrol supplementation

Group Type EXPERIMENTAL

resveratrol supplementation

Intervention Type BEHAVIORAL

6 months of resveratrol supplementation

placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type BEHAVIORAL

6 months of placebo intake

2nd step: intervention + physical /cognitive training

most effective dietary intervention plus physical and cognitive training

Group Type EXPERIMENTAL

2nd step: intervention + physical / cognitive training

Intervention Type BEHAVIORAL

most effective dietary intervention plus physical and cognitive training

2nd step: most effective dietary intervention plus control

most effective dietary intervention plus control

Group Type PLACEBO_COMPARATOR

2nd step: intervention + control

Intervention Type BEHAVIORAL

most effective dietary intervention plus control

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

caloric restriction

6 months of caloric restriction (15 %)

Intervention Type BEHAVIORAL

omega-3 supplementation

6 months of omega-3 supplementation

Intervention Type BEHAVIORAL

resveratrol supplementation

6 months of resveratrol supplementation

Intervention Type BEHAVIORAL

Placebo

6 months of placebo intake

Intervention Type BEHAVIORAL

2nd step: intervention + physical / cognitive training

most effective dietary intervention plus physical and cognitive training

Intervention Type BEHAVIORAL

2nd step: intervention + control

most effective dietary intervention plus control

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* subjects with mild cognitive impairment
* 50-80 years old
* moderate to heavy weight (BMI 25-35)

Exclusion Criteria

* dementia
* diabetes
* severe disease
* younger than 50 years
* BMI \< 25
Minimum Eligible Age

50 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

German Federal Ministry of Education and Research

OTHER_GOV

Sponsor Role collaborator

Charite University, Berlin, Germany

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Agnes Flöel

Prof. Dr. med. Agnes Flöel, Neurologie

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Agnes Floeel, Prof.

Role: STUDY_CHAIR

Charité University Berlin

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Neurology, Charité Universitätsmedizin Berlin

Berlin, , Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

References

Explore related publications, articles, or registry entries linked to this study.

Kobe T, Witte AV, Schnelle A, Lesemann A, Fabian S, Tesky VA, Pantel J, Floel A. Combined omega-3 fatty acids, aerobic exercise and cognitive stimulation prevents decline in gray matter volume of the frontal, parietal and cingulate cortex in patients with mild cognitive impairment. Neuroimage. 2016 May 1;131:226-38. doi: 10.1016/j.neuroimage.2015.09.050. Epub 2015 Oct 1.

Reference Type RESULT
PMID: 26433119 (View on PubMed)

Kobe T, Witte AV, Schnelle A, Tesky VA, Pantel J, Schuchardt JP, Hahn A, Bohlken J, Grittner U, Floel A. Impact of Resveratrol on Glucose Control, Hippocampal Structure and Connectivity, and Memory Performance in Patients with Mild Cognitive Impairment. Front Neurosci. 2017 Mar 7;11:105. doi: 10.3389/fnins.2017.00105. eCollection 2017.

Reference Type RESULT
PMID: 28326010 (View on PubMed)

Witte AV, Kobe T, Graunke A, Schuchardt JP, Hahn A, Tesky VA, Pantel J, Floel A. Impact of leptin on memory function and hippocampal structure in mild cognitive impairment. Hum Brain Mapp. 2016 Dec;37(12):4539-4549. doi: 10.1002/hbm.23327. Epub 2016 Aug 11.

Reference Type RESULT
PMID: 27511061 (View on PubMed)

Wirth M, Pichet Binette A, Brunecker P, Kobe T, Witte AV, Floel A. Divergent regional patterns of cerebral hypoperfusion and gray matter atrophy in mild cognitive impairment patients. J Cereb Blood Flow Metab. 2017 Mar;37(3):814-824. doi: 10.1177/0271678X16641128. Epub 2016 Jul 20.

Reference Type RESULT
PMID: 27037094 (View on PubMed)

Kobe T, Witte AV, Schnelle A, Grittner U, Tesky VA, Pantel J, Schuchardt JP, Hahn A, Bohlken J, Rujescu D, Floel A. Vitamin B-12 concentration, memory performance, and hippocampal structure in patients with mild cognitive impairment. Am J Clin Nutr. 2016 Apr;103(4):1045-54. doi: 10.3945/ajcn.115.116970. Epub 2016 Feb 24.

Reference Type RESULT
PMID: 26912492 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

nutrition_memory_01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.